CAR-T Meeting 2024 | The risk of secondary primary malignancy after CAR-T therapy: a retrospective analysis
Marco Ruella, MD, University of Pennsylvania, Philadelphia, PA, comments on the risk of secondary primary malignancy in patients receiving CAR T-cell therapy following an FDA warning of an increased risk of T-cell lymphoma with this treatment option. Dr Ruella highlights the findings of a retrospective study of patients receiving CAR-T, which elucidated that the incidence of secondary primary malignancy was similar to that seen with traditional chemotherapy and radiation therapy and lower than that seen with transplant. In this sample of patients, only one case of T-cell lymphoma was reported, with no CAR expression being observed in the tumor. Dr Ruella emphasizes that current evidence indicates that the incidence of secondary primary malignancy is low in this patient population and that the benefits of CAR-T therapy outweigh the risks. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Inventor: CART technologies, Univ. of Pennsylvania, partly licensed to Novartis, Tmunity, and
viTToria biotherapeutics;
Research Funding: AbClon, Beckman-Coulter, ONI, Lumicks, viTToria bio;
DSMB: PeproMene;
Consultancy/Honoraria: GLG, Guidepoint;
Advisory Board: viTToria bio, AbClon, BMS, Sana, GSK, Bayer;
Scientific Founder: viTToria biotherapeutics.
